{"product_id":"knighttx-swot-analysis","title":"Knight SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Knight’s competitive edge, operational vulnerabilities, and growth catalysts in this concise SWOT preview—designed to provoke strategic thinking for investors and managers. Want the full picture with actionable recommendations, financial context, and editable tools? Purchase the complete SWOT analysis to receive a professionally formatted Word report and Excel matrix to plan, pitch, and invest with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified product mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBalanced exposure to innovative Rx, OTC and biosimilars reduces dependence on any single category, smoothing revenue across product lifecycles and varying reimbursement regimes. This mix enables cross-selling and tailored market-entry strategies, enhancing unit economics and launch success rates. With the global biosimilars market at roughly $19.8 billion in 2023, diversification bolsters resilience against category-specific shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Canada–LatAm footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperations across Canada and multiple Latin American markets give Knight geographic diversification, tapping a LatAm market of roughly 660 million people. Local presence improves regulatory navigation and payer engagement through on-the-ground teams familiar with country-specific rules. It also enables faster commercialization via tailored go-to-market plans and creates regional optionality for portfolio allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHybrid model: own sales + partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn-house commercial teams ensure execution discipline and brand control, supporting market launches and pricing strategy. Strategic partnerships expand pipeline access while industry analyses in 2024 found collaborations can cut development capital needs by roughly 30% and shorten time-to-market by 12–18 months. The hybrid model accelerates in-licensed asset launches and builds a repeatable onboarding platform for new products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on unmet medical needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFocusing on unmet medical needs lets Knight target specialty niches with pricing power and defensible demand; specialty drugs accounted for roughly half of US drug spending by 2023, supporting premium pricing and uptake. Addressing unmet needs improves market access and physician adoption, while smaller patient populations often face less head-to-head competition, enabling durable margins. Many orphan therapies exceed annual list prices of $100,000, underscoring revenue potential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eniche pricing power\u003c\/li\u003e\n\u003cli\u003eimproved market access\u003c\/li\u003e\n\u003cli\u003elower competition\u003c\/li\u003e\n\u003cli\u003edurable margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and market-access know-how creates a high barrier to entry by managing heterogeneous regimes; efficient navigation of reimbursement, tenders and pharmacovigilance shortens launch timelines—FDA median review is 10 months (standard) vs 6 months (priority). Established processes lower approval\/compliance risk amid ~10% overall drug success rates, boosting appeal for in-licensing partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBarrier to entry: cross-border regulatory expertise\u003c\/li\u003e\n\u003cli\u003eFaster launches: FDA review benchmarks 6–10 months\u003c\/li\u003e\n\u003cli\u003eRisk reduction: ~10% drug approval success rate\u003c\/li\u003e\n\u003cli\u003eDeal flow: stronger in-licensing attractiveness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBalanced Rx\/OTC\/biosimilar portfolio; \u003cstrong\u003e$19.8B\u003c\/strong\u003e, \u003cstrong\u003e660M\u003c\/strong\u003e reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBalanced Rx\/OTC\/biosimilars mix (biosimilars $19.8B in 2023) smooths revenue; Canada + LatAm footprint taps ~660M people. In-house commercial plus partnerships cut development capital ~30% and accelerate launches 12–18 months. Focus on unmet needs supports pricing power—specialty ≈50% of US drug spend (2023); many orphan therapies \u0026gt;$100k.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars market (2023)\u003c\/td\u003e\n\u003ctd\u003e$19.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatAm population\u003c\/td\u003e\n\u003ctd\u003e~660M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share (US, 2023)\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan therapy price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab capex reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e6–10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug approval success\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise strategic overview of Knight’s internal strengths and weaknesses alongside external opportunities and threats, mapping competitive position, growth drivers, operational gaps, and key risks shaping the company’s future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, visually clear SWOT matrix that quickly pinpoints strategic pain points and prioritizes corrective actions for fast stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo U.S. market exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExcluding the U.S. cuts Knight off from nearly half of global pharma profits—US accounted for about 45% of a roughly $1.6 trillion global pharma market in 2024—constraining top-line opportunity.\u003c\/p\u003e\n\u003cp\u003eAbsence of U.S. presence reduces launch and procurement scale economies, weakens bargaining leverage with partners, and forces growth to depend on Canada (population ~38 million) and Latin America, which represent single-digit percent shares of global pharma sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct and partner concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty portfolios often hinge on a handful of SKUs, leaving revenue skewed and volatile; in 2024 the global pharmaceutical market topped about $1.5 trillion, amplifying single-product exposure. Dependence on key licensors creates termination and repricing risk that can rapidly erode margins. Loss of one product can materially dent top-line results, so diversification across indications and partners is imperative.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited internal R\u0026amp;D scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRelying on in-licensing constrains control over pipeline timing and economics, leaving Knight dependent on third-party milestones and deal terms while global pharmaceutical R\u0026amp;D investment topped roughly $200 billion in 2023, intensifying competition for late-stage assets.\u003c\/p\u003e\n\u003cp\u003eFewer proprietary assets limit long-term exclusivity and predictable revenue, as high-demand rights routinely attract multiple bidders and premium valuations that can compress deal margins.\u003c\/p\u003e\n\u003cp\u003eLimited internal R\u0026amp;D bandwidth — reflected in smaller in-house pipelines versus major peers — may cap the probability of breakthrough opportunities and force continued reliance on costly external sourcing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX and operational complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLatAm exposure drives currency volatility and inflation pressures, with regional inflation averaging about 7% in 2023–24 and major currencies (BRL, ARS) swinging \u0026gt;20% vs USD in 2023–24; multi-country operations raise compliance and logistics overhead and pricing\/tender cycles are often unpredictable; hedging only partially mitigates earnings swings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLatAm inflation ~7% (2023–24)\u003c\/li\u003e\n\u003cli\u003eCurrency swings \u0026gt;20% (BRL, ARS)\u003c\/li\u003e\n\u003cli\u003eHigher compliance\/logistics costs\u003c\/li\u003e\n\u003cli\u003eUnpredictable pricing\/tenders; hedges imperfect\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller scale vs. multinationals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSmaller scale weakens Knight’s bargaining power with manufacturers and wholesalers, especially as the three largest US wholesalers control over 85% of drug distribution, increasing procurement costs and limiting preferential terms. Promotional reach lags in specialist areas versus multinationals with global sales forces, while constrained investment capacity hinders large launches and real-world evidence generation; Phase III trials commonly exceed $100m, elevating unit costs and margin pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower bargaining power: three wholesalers \u0026gt;85% market share\u003c\/li\u003e\n\u003cli\u003ePromotion gap: narrower specialist reach vs multinationals\u003c\/li\u003e\n\u003cli\u003eInvestment limits: Phase III often \u0026gt;$100m\u003c\/li\u003e\n\u003cli\u003eScale penalty: higher per-unit costs and margin squeeze\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. exclusion cuts \u003cstrong\u003e~45%\u003c\/strong\u003e of \u003cstrong\u003e$1.6T\u003c\/strong\u003e pharma market; LatAm volatility raises risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExclusion from the U.S. market cuts Knight off from ~45% of the ~$1.6T global pharma market (2024), limiting top-line growth. Heavy reliance on in-licensing and few SKUs raises termination and concentration risk amid ~$200B global R\u0026amp;D (2023). LatAm exposure (inflation ~7%, BRL\/ARS swings \u0026gt;20%) and smaller scale reduce bargaining power vs wholesalers (\u0026gt;85% share) and raise launch costs (Phase III \u0026gt;$100m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS share (2024)\u003c\/td\u003e\n\u003ctd\u003e~45% of $1.6T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal R\u0026amp;D (2023)\u003c\/td\u003e\n\u003ctd\u003e$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatAm inflation (2023–24)\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrency swings\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20% (BRL, ARS)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers US\u003c\/td\u003e\n\u003ctd\u003eTop 3 \u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III cost\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eKnight SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the Knight SWOT Analysis you’ll receive after purchase—no surprises, just professional quality. The preview below is taken directly from the full, editable report you'll download. Buy now to unlock the complete, structured analysis ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674313408889,"sku":"knighttx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/knighttx-swot-analysis.png?v=1755788421","url":"https:\/\/portersfiveforce.com\/products\/knighttx-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}